News

Fulranumab Shows Efficacy for Osteoarthritis Pain

Publish date: July 8, 2011

 

FROM THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

Dr. Thipphawong and several of his associates are employees of Johnson & Johnson, the company developing fulranumab.

Pages

Recommended Reading

Be Cautious When Making a Diagnosis of Behçet's Disease
MDedge Family Medicine
Methadone: Safe Prescribing for Chronic Pain
MDedge Family Medicine
Opioid Rotation: Focus on Safety
MDedge Family Medicine
Tocilizumab Safety Confirmed in Real-World Setting for RA
MDedge Family Medicine
Topical Combo Shows Early Promise in Moderate Psoriasis
MDedge Family Medicine
ACPA-Negative RA Incidence Spikes During First Postpartum Year
MDedge Family Medicine
Rheumatoid Arthritis Patients Have High Expectations for Biologics
MDedge Family Medicine
Periprosthetic Joint Infections Not Increased by RA Biologics
MDedge Family Medicine
GI Perforation Rare in Rheumatoid Arthritis Patients
MDedge Family Medicine
RA and SLE Risk Factors Remain for Mothers and Babies
MDedge Family Medicine